No done deal. Your inferences are not self evident to anyone. What adjustment to p-value? Perhaps they rounded down from 0.0552 to 0.05? Otherwise no one knows what you mean. FDA says a bunch of things, let them prove what they want; as if that will disprove Leronlimab. Like I said, shareholders are interested with the critical subgroup info and the potential of LL in this regard. If FDA cares, they can talk more about that and less about what we ourselves are not talking about.
If you have a link to their Stat guidance and methods document, you can send that.
Market Data 
Markets 
AI
